XWELL, Inc. Reports Fiscal Year 2022 Results

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL), an authority in health and wellness solutions for people on the go, today reported results for the year ended December 31, 2022. Business Highlights:We’re continuing to evolve our organization and, reflecting the Company’s commitment to better serve clients, optimize efficiencies, and deliver long-term growth, management has recently: Opened 5 XpresSpa locations at Turkey’s Istanbul Airport; additional growth in Abu Dhabi during the third quarter of 2023. Opening new XpresSpa at Philadelphia International Airport in 2023. Scaled new retail products and integrated innovative health and wellness technologies, including fully autonomous HydroMassage and Human Touch® hands-free massage equipment as well as Clockwork’s AI-powered express manicure units. These three...

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces it will issue its financial results for full-year ending December 31, 2022 and provide an operational update, on Monday, April 24, 2023, after the close of the US market. This release will be followed by a conference call and live audio webcast on Tuesday, April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, prior to the open of the US market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end...

PrairieSky Announces First Quarter 2023 Results

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, April 17, 2023 (GLOBE NEWSWIRE) — PrairieSky Royalty Ltd. (“PrairieSky” or the “Company”) (TSX: PSK) is pleased to announce its first quarter (“Q1 2023”) operating and financial results for the three-month period ended March 31, 2023. First Quarter Highlights: Royalty production volumes averaged 24,809 BOE per day and included 12,212 barrels per day of oil royalty production which increased 9% over Q1 2022 and held flat with Q4 2022. Quarterly revenues of $126.1 million were comprised of royalty production revenues of $116.8 million and other revenues of $9.3 million, including bonus consideration of $5.5 million. Quarterly funds from operations totaled $86.3 million ($0.36 per share basic and diluted). Declared a dividend of $0.24 per share ($0.96 per share annualized). Net...

Baltic Horizon Fund publishes its NAV for March 2023

Written by Customer Service on April 17, 2023. Posted in Public Companies.

The net asset value (NAV) of the Baltic Horizon Fund (the Fund) unit at the end of March 2023 amounted to EUR 1.1156 per unit. Compared to the previous month, NAV per unit increased by 0.1%. The total net asset value of the Fund amounted to EUR 133.5 million over the month. The EPRA NRV as of 31 March 2023 was EUR 1.1668 per unit, corresponding to a decrease of 1.3% over the last month. Unaudited consolidated net rental income for March 2023 amounted to EUR 1.4 million (EUR 1.4 million in February 2023). The net rental income has increased by 3.0% compared to February 2023. 6 March 2023 was the closing date of the Domus Pro share sale transaction, therefore only six days of Domus Pro operating results impact the net rental income of the Fund in March 2023. The Fund recognized an unaudited consolidated net profit of EUR 0.5 million in March...

Baltic Horizon Fund publishes its NAV for March 2023

Written by Customer Service on April 17, 2023. Posted in Public Companies.

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

Written by Customer Service on April 17, 2023. Posted in Public Companies.

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monotherapy and combination arms Monotherapy dose expansion ongoing at 300 mg bid; data-informed strategy prioritizes enrollment in BRAF Class II-driven melanoma and lung cancer (33% ORR); initial data expected in the first half of 2024 Well-tolerated monotherapy backbone enables multiple development approaches, including the ongoing exarafenib combination arm in NRAS mutant melanoma; dose selection expected in the second half of 2023 SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a...

$MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023$

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

Written by Customer Service on April 17, 2023. Posted in Public Companies.

STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) — MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida. “The promising data we are sharing at AACR demonstrate the value of our next-generation RAF dimer inhibitor, BGB-3245, as a monotherapy in patients with MAPK pathway-altered...

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

Written by Customer Service on April 17, 2023. Posted in Public Companies.

Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superior cellular activity of both NX-2127 and NX-5948 against BTKi resistance mutations compared to other published BTK degraders SAN FRANCISCO, April 17, 2023 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced presentations covering its targeted protein degradation programs, including the structural disclosure of NX-2127 and new preclinical data for NX-2127 and NX-5948, highlighting their superior activity against...

Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance

Written by Customer Service on April 17, 2023. Posted in Public Companies.

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other advanced adult solid tumors, is expected to enter the clinic in the first half of 2024 Kinnate to evaluate strategic alternatives for its CDK12 program ~$231 million of cash, cash equivalents and investments as of March 31, 2023 is anticipated to fund planned operations into early 2025 Kinnate to host virtual investor webcast today, April 17, 2023, at 5:30 pm ET SAN FRANCISCO and SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced the addition...

$SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023$

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Written by Customer Service on April 17, 2023. Posted in Public Companies.

STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberrations. The data are being presented today in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place in Orlando, Florida. “The lifirafenib plus mirdametinib combination represents a novel targeted approach to treat solid tumors driven by RAS/RAF mutations, and...

Day: April 17, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice